ProteoGenix and Cizzle Biotechnology Collaboration Advances Early Lung Cancer Detection

NewsCollaborations and Partnerships
Written By Cizzle Bio, Inc.

Innovative Antibody Development

ProteoGenix and Cizzle Biotechnology Holdings PLC have successfully developed new antibodies targeting the CIZ1B biomarker, associated with early-stage lung cancer. This collaboration promises to enhance early detection methods, addressing critical diagnostic needs.

Key Points:

  • Enhanced Detection:

    New antibodies improve early lung cancer diagnostics.

  • Collaborative Success:

    Combines ProteoGenix's antibody expertise with Cizzle's diagnostic focus.

  • Future Impact:

    Aims for rapid commercialization and improved patient outcomes.

For more details, read the full article on Pressat: ProteoGenix and Cizzle Biotechnology Collaboration.

Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Previous

Cizzle Biotechnology's £0.62 Million Fundraising and Strategic Developments
Next

Strategic Licensing and Partnership: Cizzle Bio Inc.